CN113557300A - 核酸序列、rna目标区域测序文库的构建方法及应用 - Google Patents
核酸序列、rna目标区域测序文库的构建方法及应用 Download PDFInfo
- Publication number
- CN113557300A CN113557300A CN201980091855.0A CN201980091855A CN113557300A CN 113557300 A CN113557300 A CN 113557300A CN 201980091855 A CN201980091855 A CN 201980091855A CN 113557300 A CN113557300 A CN 113557300A
- Authority
- CN
- China
- Prior art keywords
- sequence
- primer
- sequencing
- universal
- rna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000012163 sequencing technique Methods 0.000 title claims abstract description 104
- 150000007523 nucleic acids Chemical group 0.000 title claims abstract description 48
- 108091028043 Nucleic acid sequence Proteins 0.000 title claims abstract description 38
- 238000010276 construction Methods 0.000 title claims abstract description 10
- 238000011144 upstream manufacturing Methods 0.000 claims abstract description 53
- 238000010839 reverse transcription Methods 0.000 claims abstract description 29
- 239000002299 complementary DNA Substances 0.000 claims abstract description 25
- 239000002773 nucleotide Substances 0.000 claims abstract description 14
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 14
- 238000007857 nested PCR Methods 0.000 claims abstract description 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 58
- 108090000623 proteins and genes Proteins 0.000 claims description 58
- 230000004927 fusion Effects 0.000 claims description 47
- 238000000034 method Methods 0.000 claims description 41
- 230000003321 amplification Effects 0.000 claims description 28
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 28
- 230000000295 complement effect Effects 0.000 claims description 24
- 230000027455 binding Effects 0.000 claims description 21
- 239000013614 RNA sample Substances 0.000 claims description 19
- 238000012408 PCR amplification Methods 0.000 claims description 12
- 102100034343 Integrase Human genes 0.000 claims description 8
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 claims description 8
- 238000006243 chemical reaction Methods 0.000 claims description 8
- 108020004414 DNA Proteins 0.000 claims description 7
- 108091092259 cell-free RNA Proteins 0.000 claims description 6
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims description 5
- 239000012634 fragment Substances 0.000 claims description 4
- 230000035772 mutation Effects 0.000 claims description 4
- 238000012224 gene deletion Methods 0.000 claims description 2
- 238000003780 insertion Methods 0.000 claims description 2
- 230000037431 insertion Effects 0.000 claims description 2
- 230000007614 genetic variation Effects 0.000 claims 1
- 238000001514 detection method Methods 0.000 description 15
- 238000003559 RNA-seq method Methods 0.000 description 12
- 238000005516 engineering process Methods 0.000 description 11
- 230000014509 gene expression Effects 0.000 description 9
- 108020004999 messenger RNA Proteins 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- 238000003908 quality control method Methods 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 239000011324 bead Substances 0.000 description 6
- 102100027100 Echinoderm microtubule-associated protein-like 4 Human genes 0.000 description 5
- 101001057929 Homo sapiens Echinoderm microtubule-associated protein-like 4 Proteins 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 102100033793 ALK tyrosine kinase receptor Human genes 0.000 description 3
- 102100027094 Echinoderm microtubule-associated protein-like 1 Human genes 0.000 description 3
- 101001057941 Homo sapiens Echinoderm microtubule-associated protein-like 1 Proteins 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 238000013467 fragmentation Methods 0.000 description 3
- 238000006062 fragmentation reaction Methods 0.000 description 3
- 238000012165 high-throughput sequencing Methods 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 238000007403 mPCR Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 101150023956 ALK gene Proteins 0.000 description 2
- 108700024394 Exon Proteins 0.000 description 2
- 101000823316 Homo sapiens Tyrosine-protein kinase ABL1 Proteins 0.000 description 2
- 108091092195 Intron Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 102100022596 Tyrosine-protein kinase ABL1 Human genes 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 101150068690 eml4 gene Proteins 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 description 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 101000638154 Homo sapiens Transmembrane protease serine 2 Proteins 0.000 description 1
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
- 239000002146 L01XE16 - Crizotinib Substances 0.000 description 1
- 241000713869 Moloney murine leukemia virus Species 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 230000009948 RNA mutation Effects 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- 101150077555 Ret gene Proteins 0.000 description 1
- 101150035397 Ros1 gene Proteins 0.000 description 1
- 102100031989 Transmembrane protease serine 2 Human genes 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229940062527 alendronate Drugs 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 229960005061 crizotinib Drugs 0.000 description 1
- KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 description 1
- 230000002380 cytological effect Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000013090 high-throughput technology Methods 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 150000004713 phosphodiesters Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229960003787 sorafenib Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 210000001324 spliceosome Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229960001796 sunitinib Drugs 0.000 description 1
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
- C40B50/06—Biochemical methods, e.g. using enzymes or whole viable microorganisms
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Plant Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
提供了一种核酸序列以及RNA目标区域测序文库的构建方法及应用。该核酸序列包含相连的位于5’端的第一测序通用序列和位于3’端的随机引物序列,随机引物序列含有6~10个随机核苷酸。利用该序列对RNA进行随机的逆转录,得到cDNA的第一链,然后通过该核酸序列上的第一测序通用序列以及上下游特异性引物对逆转录得到的cDNA第一条链进行2步巢式PCR,得到高通量靶向测序文库。
Description
PCT国内申请,说明书已公开。
Claims (16)
- PCT国内申请,权利要求书已公开。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2019/079235 WO2020191521A1 (zh) | 2019-03-22 | 2019-03-22 | 核酸序列、rna目标区域测序文库的构建方法及应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113557300A true CN113557300A (zh) | 2021-10-26 |
Family
ID=72610369
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201980091855.0A Pending CN113557300A (zh) | 2019-03-22 | 2019-03-22 | 核酸序列、rna目标区域测序文库的构建方法及应用 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN113557300A (zh) |
WO (1) | WO2020191521A1 (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114317685A (zh) * | 2022-01-05 | 2022-04-12 | 苏州贝康医疗器械有限公司 | 用于检测mRNA可变剪切变异的试剂盒、建库方法和测序方法 |
CN117343989A (zh) * | 2023-12-06 | 2024-01-05 | 广州迈景基因医学科技有限公司 | 一种检测基因融合的靶向建库方法 |
WO2024119481A1 (zh) * | 2022-12-09 | 2024-06-13 | 深圳华大智造科技股份有限公司 | 一种快速制备多重pcr测序文库的方法及其应用 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116042770B (zh) * | 2022-11-01 | 2023-12-01 | 苏州京脉生物科技有限公司 | 尿液中miRNA文库制备和表达定量的方法及试剂盒 |
CN117887812B (zh) * | 2024-03-14 | 2024-07-09 | 北京雅康博生物科技有限公司 | 高通量测序质控用文库及其制备方法和应用 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040209298A1 (en) * | 2003-03-07 | 2004-10-21 | Emmanuel Kamberov | Amplification and analysis of whole genome and whole transcriptome libraries generated by a DNA polymerization process |
CN101871004A (zh) * | 2009-04-27 | 2010-10-27 | 冯长访 | 成熟miRNA定量检测方法及试剂盒 |
CN105154567A (zh) * | 2015-10-16 | 2015-12-16 | 上海交通大学 | 基于高通量测序的研究与目标蛋白结合的rna的方法 |
CN106715714A (zh) * | 2014-10-17 | 2017-05-24 | 深圳华大基因研究院 | 一种用于核酸随机片段化的引物及核酸随机片段化方法 |
CN106929504A (zh) * | 2015-12-30 | 2017-07-07 | 安诺优达基因科技(北京)有限公司 | 检测急性早幼粒细胞白血病相关融合基因的试剂盒 |
CN107385042A (zh) * | 2017-07-28 | 2017-11-24 | 广州永诺健康科技有限公司 | 一种锚定巢式多重 pcr 联合高通量测序检测基因融合的多重pcr引物和方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102732598B (zh) * | 2011-04-11 | 2017-03-01 | 陈先锋 | 一种全基因组dna序列拼接测序方法 |
CN107075561A (zh) * | 2014-10-13 | 2017-08-18 | 深圳华大基因科技有限公司 | 一种核酸片段化方法和序列组合 |
CN105714383B (zh) * | 2014-12-22 | 2018-01-23 | 深圳华大基因研究院 | 一种基于分子反向探针的测序文库构建方法和试剂 |
CN107502607A (zh) * | 2017-06-20 | 2017-12-22 | 浙江大学 | 一种大量组织、细胞样本mRNA的分子条形码标记、文库构建、测序的方法 |
CN108588176A (zh) * | 2018-05-06 | 2018-09-28 | 湖南大地同年生物科技有限公司 | 一种基于单链DNA构建R-loop高通量测序文库的方法 |
CN109097467A (zh) * | 2018-08-08 | 2018-12-28 | 江苏苏博生物医学科技南京有限公司 | 基于illumina平台的乳腺癌分型检测试剂盒及应用 |
CN109295500B (zh) * | 2018-09-26 | 2022-02-01 | 博奥生物集团有限公司 | 一种单细胞甲基化测序技术及其应用 |
-
2019
- 2019-03-22 CN CN201980091855.0A patent/CN113557300A/zh active Pending
- 2019-03-22 WO PCT/CN2019/079235 patent/WO2020191521A1/zh active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040209298A1 (en) * | 2003-03-07 | 2004-10-21 | Emmanuel Kamberov | Amplification and analysis of whole genome and whole transcriptome libraries generated by a DNA polymerization process |
CN101871004A (zh) * | 2009-04-27 | 2010-10-27 | 冯长访 | 成熟miRNA定量检测方法及试剂盒 |
CN106715714A (zh) * | 2014-10-17 | 2017-05-24 | 深圳华大基因研究院 | 一种用于核酸随机片段化的引物及核酸随机片段化方法 |
CN105154567A (zh) * | 2015-10-16 | 2015-12-16 | 上海交通大学 | 基于高通量测序的研究与目标蛋白结合的rna的方法 |
CN106929504A (zh) * | 2015-12-30 | 2017-07-07 | 安诺优达基因科技(北京)有限公司 | 检测急性早幼粒细胞白血病相关融合基因的试剂盒 |
CN107385042A (zh) * | 2017-07-28 | 2017-11-24 | 广州永诺健康科技有限公司 | 一种锚定巢式多重 pcr 联合高通量测序检测基因融合的多重pcr引物和方法 |
Non-Patent Citations (2)
Title |
---|
JING ZHAO 等: ""Genome-wide identification of Polycomb-associated RNAs by RIP-seq"", 《MOL CELL》, vol. 40, no. 6, pages 8 * |
姚文秀 等: ""EML4-ALK融合基因重排对晚期非小细胞肺癌诊断及治疗价值"", 《肿瘤预防与治疗》, vol. 30, no. 5, pages 390 - 395 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114317685A (zh) * | 2022-01-05 | 2022-04-12 | 苏州贝康医疗器械有限公司 | 用于检测mRNA可变剪切变异的试剂盒、建库方法和测序方法 |
CN114317685B (zh) * | 2022-01-05 | 2023-10-20 | 苏州贝康医疗器械有限公司 | 用于检测mRNA可变剪切变异的试剂盒、建库方法和测序方法 |
WO2024119481A1 (zh) * | 2022-12-09 | 2024-06-13 | 深圳华大智造科技股份有限公司 | 一种快速制备多重pcr测序文库的方法及其应用 |
CN117343989A (zh) * | 2023-12-06 | 2024-01-05 | 广州迈景基因医学科技有限公司 | 一种检测基因融合的靶向建库方法 |
CN117343989B (zh) * | 2023-12-06 | 2024-05-17 | 广州迈景基因医学科技有限公司 | 一种检测基因融合的靶向建库方法 |
Also Published As
Publication number | Publication date |
---|---|
WO2020191521A1 (zh) | 2020-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6664025B2 (ja) | まれな変異およびコピー数多型を検出するためのシステムおよび方法 | |
Del Vecchio et al. | Next-generation sequencing: recent applications to the analysis of colorectal cancer | |
CN113557300A (zh) | 核酸序列、rna目标区域测序文库的构建方法及应用 | |
US20150126376A1 (en) | Compositions and methods for sensitive mutation detection in nucleic acid molecules | |
EP3285193A1 (en) | Method for predicting organ transplant rejection using next-generation sequencing | |
CN107475375A (zh) | 一种用于与微卫星不稳定性相关微卫星位点进行杂交的dna探针库、检测方法和试剂盒 | |
CN114774520A (zh) | 检测肿瘤发展的系统和方法 | |
CN106834515B (zh) | 一种检测met基因14外显子突变的探针库、检测方法和试剂盒 | |
US20160340725A1 (en) | Method to increase sensitivity of next generation sequencing | |
EP3607065B1 (en) | Method and kit for constructing nucleic acid library | |
CN104745679A (zh) | 一种无创检测egfr基因突变的方法及试剂盒 | |
WO2013037118A1 (zh) | 前列腺癌的生物学标志物、治疗靶点及其用途 | |
CN105420351A (zh) | 确定个体基因突变的方法和系统 | |
CN111979583B (zh) | 一种单链核酸分子高通量测序文库的构建方法及其应用 | |
JP2023054163A (ja) | 融合遺伝子及び/又はエクソンスキッピングにより生ずる転写産物を検出するためのプローブ及び方法 | |
CN109666745A (zh) | 染色体1p/19q联合杂合性缺失的检测方法及试剂盒 | |
CN106520917A (zh) | 一种基因的大片段缺失/重复检测的方法 | |
JP2021528094A (ja) | マイクロサテライト不安定性の検出 | |
CN105779432A (zh) | 试剂盒及其用途 | |
US20210115503A1 (en) | Nucleic acid capture method | |
US20180291369A1 (en) | Error-proof nucleic acid library construction method and kit | |
US20180291436A1 (en) | Nucleic acid capture method and kit | |
Wang et al. | Targeted sequencing of both DNA strands barcoded and captured individually by RNA probes to identify genome-wide ultra-rare mutations | |
CN103667267B (zh) | 用于与kras基因杂交的dna探针库及采用其富集kras基因片段的方法 | |
WO2017035821A1 (zh) | RNA 5mC重亚硫酸盐测序的文库构建方法及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |